Encephalopathy - A Pipeline Analysis Report

Overview of the drug development for encephalopathy

Encephalopathy is a common brain disease or malfunction of the brain. It is a syndrome that is characterized by multiple brain disorders. It may be caused by metabolic or mitochondrial dysfunction, infectious agents, increased pressure in the skull, prolonged exposure to toxins, chronic progressive trauma, or lack of oxygen or poor nutrition of blood flow to the brain. It differs from person to person and can be both temporary and permanent. Furthermore, bacterial infection, liver damage, brain anoxia, and kidney failure are the common causes of encephalopathy. The disease can develop at any age and can be present at the time of birth or may never be cured. According to the NIH, 30%-45% of people with liver cirrhosis have hepatic encephalopathy. As a result, with rising incidences of the disease, the drug development for encephalopathy is likely to increase considerably in the forthcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for DS. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Encephalopathy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Aquestive Therapeutics
• ASKA Pharmaceutical
• BrainRepair
• CELGENE

Therapeutic assessment of the drug development for encephalopathy by route of administration

• Oral
• Intravenous
• Parenteral
• Transdermal
• Intravenous/subcutaneous
• Intranasal

The oral route of administration (ROA) involves the application of the drug directly in to the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for encephalopathy by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development for encephalopathy are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for encephalopathy?
• What are the companies that are currently involved in the development of drug molecules for encephalopathy?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.